As of April 16, 2025, UroGen Pharma (URGN) has a market cap of $0.50 billion USD. According to our data, UroGen Pharma is ranked No.5981 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 16, 2025 | $0.50 B |
10.26%
|
Dec 31, 2024 | $0.45 B |
-29.00%
|
Dec 29, 2023 | $0.63 B |
69.11%
|
Dec 30, 2022 | $0.37 B |
-6.73%
|
Dec 31, 2021 | $0.40 B |
-47.23%
|
Dec 31, 2020 | $0.76 B |
-46.00%
|
Dec 31, 2019 | $1.41 B |
-22.50%
|
Dec 31, 2018 | $1.82 B |
15.72%
|
Dec 29, 2017 | $1.57 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Nektar Therapeutics
NKTR
|
$0.12 B |
0.000 M
|
![]() USA
|
![]() Karyopharm Therapeutics
KPTI
|
$35.85 M |
-0.000 M
|
![]() USA
|
![]() Syndax Pharmaceuticals
SNDX
|
$0.97 B |
0.000 M
|
![]() USA
|
![]() Blueprint Medicines
BPMC
|
$5.21 B |
0.000 M
|
![]() USA
|
![]() Exelixis
EXEL
|
$10.23 B |
0.000 M
|
![]() USA
|
![]() Incyte
INCY
|
$11.31 B |
0.000 M
|
![]() USA
|
![]() MacroGenics
MGNX
|
$79.49 M |
-0.000 M
|
![]() USA
|
![]() Zymeworks
ZYME
|
$0.76 B |
-0.000 M
|
![]() Canada
|
![]() Iovance Biotherapeutics
IOVA
|
$1.06 B |
-0.000 M
|
![]() USA
|
![]() Adaptimmune Therapeutics
ADAP
|
$64.18 M |
-0.000 M
|
![]() UK
|
![]() Allogene Therapeutics
ALLO
|
$0.32 B |
0.000 M
|
![]() USA
|
![]() Arcus Biosciences
RCUS
|
$0.85 B |
-0.000 M
|
![]() USA
|
Market Cap | = | URGN Stock Price | * | URGN Shares Outstanding |
= | $10.75 | * | 46.09 M | |
= | $0.50 B |